image
Healthcare - Biotechnology - NASDAQ - US
$ 14.925
-4.77 %
$ 103 M
Market Cap
-0.08
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TNXP stock under the worst case scenario is HIDDEN Compared to the current market price of 14.9 USD, Tonix Pharmaceuticals Holding Corp. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TNXP stock under the base case scenario is HIDDEN Compared to the current market price of 14.9 USD, Tonix Pharmaceuticals Holding Corp. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TNXP stock under the best case scenario is HIDDEN Compared to the current market price of 14.9 USD, Tonix Pharmaceuticals Holding Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TNXP

image
$70.0$70.0$60.0$60.0$50.0$50.0$40.0$40.0$30.0$30.0$20.0$20.0$10.0$10.0$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
10.1 M REVENUE
29.94%
-137 M OPERATING INCOME
-15.48%
-130 M NET INCOME
-11.47%
-60.9 M OPERATING CASH FLOW
40.27%
-120 K INVESTING CASH FLOW
99.59%
135 M FINANCING CASH FLOW
269.34%
2.58 M REVENUE
-8.50%
-22.5 M OPERATING INCOME
-44.53%
-22.1 M NET INCOME
-55.55%
-14.6 M OPERATING CASH FLOW
22.18%
-3 K INVESTING CASH FLOW
66.67%
85.2 M FINANCING CASH FLOW
98.47%
Balance Sheet Tonix Pharmaceuticals Holding Corp.
image
Current Assets 119 M
Cash & Short-Term Investments 98.8 M
Receivables 8.08 M
Other Current Assets 12.1 M
Non-Current Assets 43.9 M
Long-Term Investments 0
PP&E 42.8 M
Other Non-Current Assets 1.07 M
60.64 %4.96 %7.45 %26.29 %Total Assets$162.9m
Current Liabilities 18.3 M
Accounts Payable 4.55 M
Short-Term Debt 3.09 M
Other Current Liabilities 10.7 M
Non-Current Liabilities 5.02 M
Long-Term Debt 5.02 M
Other Non-Current Liabilities 0
19.48 %13.26 %45.72 %21.54 %Total Liabilities$23.3m
EFFICIENCY
Earnings Waterfall Tonix Pharmaceuticals Holding Corp.
image
Revenue 10.1 M
Cost Of Revenue 7.76 M
Gross Profit 2.33 M
Operating Expenses 139 M
Operating Income -137 M
Other Expenses -6.66 M
Net Income -130 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)10m(8m)2m(139m)(137m)7m(130m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
23.07% GROSS MARGIN
23.07%
-1354.28% OPERATING MARGIN
-1354.28%
-1288.25% NET MARGIN
-1288.25%
-93.18% ROE
-93.18%
-79.83% ROA
-79.83%
-92.57% ROIC
-92.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tonix Pharmaceuticals Holding Corp.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -130 M
Depreciation & Amortization 3.42 M
Capital Expenditures -120 K
Stock-Based Compensation 4.78 M
Change in Working Capital 5.78 M
Others 62.2 M
Free Cash Flow -61 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tonix Pharmaceuticals Holding Corp.
image
TNXP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Tonix Pharmaceuticals Holding Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C. globenewswire.com - 2 weeks ago
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies Agreement includes the use of Tonix's TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana's genetically engineered pig organs in xenotransplantation globenewswire.com - 3 weeks ago
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia globenewswire.com - 3 weeks ago
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D. globenewswire.com - 1 month ago
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a fully-integrated digital platform designed to help patients better understand and manage their migraine condition. globenewswire.com - 1 month ago
Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. accessnewswire.com - 1 month ago
Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D. globenewswire.com - 1 month ago
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years PDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Committee Meeting of TNX-102 SL for the treatment of patients with Fibromyalgia. TNX-102 SL met primary endpoints in two Phase 3 studies, showing significant pain reduction, positioning it as the first new Fibromyalgia drug in 15 years. seekingalpha.com - 1 month ago
Pharma Frenzy: Volatility Ignites Biotech Sector The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO. The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions. marketbeat.com - 1 month ago
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025 CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Company's New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia. globenewswire.com - 1 month ago
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading - infects mostly gay men CHATHAM, NJ / ACCESS Newswire / March 20, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. accessnewswire.com - 1 month ago
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. benzinga.com - 1 month ago
8. Profile Summary

Tonix Pharmaceuticals Holding Corp. TNXP

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 103 M
Dividend Yield 0.00%
Description Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Contact 26 Main Street, Chatham, NJ, 07928 https://www.tonixpharma.com
IPO Date May 10, 2012
Employees 81
Officers Dr. Gregory M. Sullivan M.D. Chief Medical Officer & Secretary Dr. Zeil Rosenberg M.D., M.P.H. Executive Vice President of Medical Dr. Seth Lederman M.D. Co-Founder, President, Chief Executive Officer & Chairman Ms. Siobhan Fogarty B.Sc., M.Sc. Chief Technical Officer Dr. Darryl Rideout Ph.D. Executive Vice President of Experimental Chemistry Mrs. Jessica Edgar Morris Chief Operating Officer Mr. Bradley Saenger CPA Chief Financial Officer & Treasurer Dr. Sina Bavari Ph.D. Executive Vice President of Infectious Disease Research & Development Mr. Thomas Englese M.B.A. Executive Vice President of Commercial Operations